Alosenta was pleased to take part in the Cancer Tech Accelerator Founder & Investor Evening in London this February, held at the London Institute for Healthcare Engineering.
As an alumni company, it was great to be back within the ecosystem. It continues to bring together founders, clinicians, investors, and operators focused on advancing oncology innovation.
Our Commercial Lead, Judy Kingswolf-Yamakawa, joined as a speaker, pitching and sharing Alosenta’s perspective on reducing failure across the drug development lifecycle. With ~90% of clinical candidates failing, most often due to toxicity, there is a clear need to intervene earlier with better modelling and smarter delivery strategies.
Thank you to the Cancer Tech Accelerator team for hosting a thoughtful and well-curated evening. We look forward to continuing to build alongside this community.